Business Wire

CA-AIRSPACE-TECH

10.12.2020 14:02:12 CET | Business Wire | Press release

Share
Airspace Technologies Announces International Expansion to Support Time-Critical Shipments

Airspace Technologies, Inc. (Airspace), the company revolutionizing air cargo and time-critical logistics, has opened its first European office, with the launch of Airspace B.V. From the headquarters, located at Schiphol-Rijk, the Netherlands, which opened in June this year, Airspace will be expanding its team across the Netherlands, France, Germany, and the U.K., in line with its rapid growth plans to fulfill customer demand.

Airspace’s technology is transforming and modernizing the logistics industry. Their proprietary software uses machine learning to identify the fastest and lowest risk path out of millions of possibilities. The technology proactively ensures that any potential delays are avoided and guarantees the customer real-time, end-to-end visibility. While officials anticipate significant problems at the borders due to Brexit, Airspace’s technology will greatly reduce the impact of the logistics issues for the customer and allow vital products and services to still be delivered on time.

The new European operation will be managed by Marcel Andriessen, who has successfully led logistics companies specializing in worldwide time-critical services over the last 20 years. Andriessen was the Managing Director at time:matters for 10 years and was responsible for the success of their European business and the expansion into the U.S. Andriessen will lead the Airspace BV organization as Managing Director.

“I am looking forward to getting back into time-critical logistics and to bring Airspace’s leading-edge technology to the European market. Customers here have not experienced the speed and transparency that Airspace offers, and I welcome the opportunity to show them how much better time-critical logistics can be,” said Andriessen.

The company’s expansion is in response to the demand from global customers who want to further leverage the Airspace technology for their European operations. Industry-leading customers including Quest Diagnostics, Varian Medical, and Allegiant Air Corporation, already rely on Airspace’s proprietary logistics technology and robust delivery network to deliver their mission-critical shipments as fast as possible throughout North America and Europe. They rely on the technology platform Airspace has developed to provide real-time, door-to-door transparency throughout the entire shipment process. This is most important for life-saving industries, such as the medical profession, which depend on rapid deliveries.

“The time-critical market is full of difficult problems. Customers too often have a poor experience because the industry is trying to solve these problems using antiquated practices. Shippers across Europe need a modern platform that can provide the level of transparency and error prevention that these critical shipments deserve,” said Nick Bulcao, Co-Founder & CEO of Airspace Technologies, Inc.

About Airspace Technologies, Inc.

Based in Carlsbad, Calif., Airspace Technologies, Inc. was founded in 2015 and has grown to be the most trusted leader in time-critical logistics. Airspace makes shipping faster, safer, and more transparent than ever through people, service, and technology. From real-time, data-driven notifications to tracking over 16,000 touchpoints within a shipment, Airspace surfaces more information than any other provider, increasing the velocity and transparency of the supply chain.

To learn more about Airspace, please visit www.airspacetechnologies.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye